Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
Jalili
Ahmad
A
Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Allgemeines Krankenhaus, Währinger Gürtel 18-20, A-1090 Vienna, Austria. ahmad.jalili@meduniwien.ac.at
Kinaciyan
Tamar
T
Barisani
Talin
T
Peck-Radosavljevic
Markus
M
Stingl
Georg
G
Geusau
Alexandra
A
Wöhrl
Stefan
S
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D015235:HLA-B Antigens / Q000235:genetics; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D000068698:Tenofovir; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D019562:Viral Load
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D015235:HLA-B Antigens; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000068698:Tenofovir; D000069285:Infliximab; D000225:Adenine